McKesson (MCK) concluded the recent trading session at $585.08, signifying a +0.57% move from its prior day's close.
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
MCK aims to focus on capital deployment and prioritize investments to strengthen its strategic oncology and biopharma growth platforms.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today December 19th:
MCK's strategic collaborations and strength in Biologics raise optimism about the stock.
Becton, Dickinson, BD, McKesson, Cardinal Health and Merit Medical Systems have been highlighted in this Industry Outlook article.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson Corporation (NYSE:MCK ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 8:20 AM ET Company Participants Britt Vitalone - Executive Vice President and Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Elizabeth Anderson Thank you for joining us this morning. Appreciate you coming by.